【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Eye: An Overview of Its Structure and Function
2.3 The Global Burden of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: the ‘Silent Thief of Sight’
2.5.1 A Classification of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors for Glaucoma
2.5.3 Diagnosis of Glaucoma
2.5.4 Drug Treatment of Glaucoma
2.5.5 Laser Treatment and Surgery for Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors for AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis of Diabetic Retinopathy
2.7.2 Treatment of Diabetic Retinopathy
2.8 Ocular Allergy and Allergic Conjunctivitis
2.8.1 Diagnosis of Ocular Allergy
2.8.2 Treatment of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Scope of this Report
2.14 Currency Exchange Rates in This Report
3. Ophthalmic Drugs: World Market 2014-2024
3.1 The World Ophthalmic Drugs Market in 2013
3.1.1 Leading Ophthalmic Drugs
3.1.2 Leading Companies in the Ophthalmic Drugs Market
3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024
3.3 Retinal Disorder Drugs Lead the World Ophthalmic Drugs Market
3.4 How Will Segmental Market Shares Change to 2024?
3.4.1 World Ophthalmic Drugs Market: Drivers and Restraints 2014-2024
4. Leading National Markets 2014-2024
4.1 Geographical Breakdown of the World Ophthalmic Drugs Market
4.2 World Ophthalmic Drugs Market: National Markets Forecast 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Ophthalmic Drugs Market 2014-2024
4.3.1 US Ophthalmic Drugs Market Forecast 2014-2024
4.3.2 US Ophthalmic Drugs Market: Trends and Developments
4.3.2.1 Affordable Care Act: Expanding Medicare Coverage
4.3.2.2 A US Biosimilars Market?
4.4 Japanese Ophthalmic Drugs Market 2014-2024
4.4.1 Japanese Ophthalmic Drugs Market Forecast 2014-2024
4.4.2 Japanese Ophthalmic Drugs Market: Trends and Developments
4.4.2.1 The Cost of Treatment in Japan
4.5 Chinese Ophthalmic Drugs Market 2014-2024
4.5.1 Chinese Ophthalmic Drugs Market Forecast 2014-2024
4.5.2 Chinese Ophthalmic Drugs Market: Trends and Developments
4.5.2.1 Expansion of Healthcare Coverage and Reimbursement
4.5.2.2 Price Controls and the Anhui Model
4.6 EU5 Ophthalmic Drugs Market 2014-2024
4.6.1 German Ophthalmic Drugs Market Forecast 2014-2024
4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024
4.6.3 UK Ophthalmic Drugs Market Forecast 2014-2024
4.6.4 Italian Ophthalmic Drugs Market Forecast 2014-2024
4.6.5 Spanish Ophthalmic Drugs Market Forecast 2014-2024
4.7 Brazilian Ophthalmic Drugs Market 2014-2024
4.7.1 Brazilian Ophthalmic Drugs Market Forecast 2014-2024
4.7.2 Brazilian Ophthalmic Drugs Market: Trends and Developments
4.7.2.1 Increasing Access to Medicines
4.8 Russian Ophthalmic Drugs Market 2014-2024
4.8.1 Russian Ophthalmic Drugs Market Forecast 2014-2024
4.8.2 Russian Ophthalmic Drugs Market: Trends and Developments
4.8.2.1 Pharma2020, Healthcare and Industry Reform
4.9 Indian Ophthalmic Drugs Market 2014-2024
4.9.1 Indian Ophthalmic Drugs Market Forecast 2014-2024
4.9.2 Indian Ophthalmic Drugs Market: Trends and Developments
4.9.2.1 Drug Prices Control Order 2013
4.9.2.2 Expansion of Healthcare Provision
4.10 Mexican Ophthalmic Drugs Market 2014-2024
4.10.1 Mexican Ophthalmic Drugs Market Forecast 2014-2024
4.10.2 Mexican Ophthalmic Drugs Market: Trends and Developments
4.10.2.1 Lupin Acquires Laboratorios Grin, Entering the Mexican Market
4.10.2.2 Seguro Popular: Mexican Healthcare Reform
4.10.2.3 International Interest in Mexico
5. Retinal Disorder Drugs Market 2014-2024
5.1 Retinal Disorder Drugs: the Rise of Anti-VEGF Therapy
5.2 Leading Retinal Disorder Drugs in 2013
5.3 Retinal Disorder Drugs: Market Forecast 2014-2024
5.4 Market Share of Leading Retinal Disorder Drugs to 2024
5.5 Retinal Disorder Drugs: Trends and Developments
5.5.1 Lucentis Dominates the Retinal Disorder Drugs Market
5.5.2 Roche and Novartis Fined Over Lucentis-Avastin Collusion
5.5.3 Requiring Avastin Use in AMD?
5.5.4 Novartis Licenses Ophthotech’s Fovista
5.5.5 Jetrea Launch Disappoints Analysts
5.5.6 Conbercept Approved in China
5.5.7 Drug/Device Combination Products Entering the Market
5.5.8 Advances in Regenerative Medicine
5.6 Lucentis (ranibizumab, Roche/Novartis)
5.6.1 Lucentis: Sales Forecast 2014-2024
5.6.2 Less Frequent Dosing Approved in US
5.6.3 New Indications for Lucentis
5.6.4 Lucentis/Fovista Combination Therapy?
5.7 Eylea (aflibercept, Regeneron/Bayer/Santen)
5.7.1 Eylea: Sales Forecast 2014-2024
5.7.2 The Comparative Efficacy of Eylea
5.7.3 Combination Therapy with Eylea and a PDGFR-beta Inhibitor
5.8 Avastin (bevacizumab, Roche)
5.8.1 Avastin: Sales Forecast 2014-2024
5.8.2 Compounding Pharmacies and Safety Risks
5.9 Visudyne (verteporfin, Valeant/Novartis)
5.9.1 Visudyne: Sales Forecast 2014-2024
5.10 Jetrea (ocriplasmin, ThromboGenics/Novartis)
5.10.1 Jetrea: Sales Forecast 2014-2024
5.10.2 Potential Acquisition of ThromboGenics?
5.10.3 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
5.11 Other Retinal Disorder Drugs
5.11.1 Iluvien (fluocinolone implant, Alimera Sciences)
5.11.2 Ozurdex (dexamethasone implant, Allergan)
6. Allergic, Inflammatory and Infective Drugs Market 2014-2024
6.1 Allergic, Inflammatory and Infective Drugs: Introduction
6.2 Allergic, Inflammatory and Infective Drugs: Submarket Breakdown
6.3 Leading Allergic, Inflammatory and Infective Drugs in 2013
6.4 Allergic, Inflammatory and Infective Drugs: Market Forecast 2014-2024
6.5 Market Share of Leading Allergic, Inflammatory and Infective Drugs to 2024
6.6 Allergic, Inflammatory and Infective Drugs: Trends and Developments
6.6.1 Growth Prospects in 2014-2024
6.6.2Lupin Launches Generic Zymaxid
6.6.3 New Topical NSAIDs Launched: Prolensa and Ilevro
6.7 Patanol and Pataday (olopatadine, Alcon)
6.7.1 Patanol: Sales Forecast 2014-2024
6.7.2 Pataday: Sales Forecast 2014-2024
6.7.3 Generic Competition for Patanol/Pataday?
6.8 Vigamox (moxifloxacin, Alcon)
6.8.1 Vigamox: Sales Forecast 2014-2024
6.8.2 Generic Challenges to Vigamox
6.8.3 Moxeza: A Next-Generation Form of Vigamox
6.9 TobraDex (tobramycin/dexamethasone, Alcon)
6.9.1 TobraDex: Sales Forecast 2014-2024
6.9.2 TobraDex ST (Alcon/Novartis)
6.10 Bromday (bromfenac, Valeant)
6.10.1 Bromday: Sales Forecast 2014-2024
6.10.2 Prolensa: A New Formulation of Bromfenac
6.10.3 Competition from Ilevro/Nevanac
6.11 Cravit (levofloxacin, Santen)
6.11.1 Cravit: Sales Forecast 2014-2024
6.12 Acular (ketorolac, Allergan)
6.12.1 Acular: Sales Forecast 2014-2024
6.13 AzaSite (azithromycin, Akorn)
6.13.1 AzaSite: Sales Forecast 2014-2024
7. Glaucoma Drugs Market 2014-2024
7.1 Glaucoma: Prostaglandin Analogues Lead the Market
7.2 Leading Glaucoma Drugs in 2013
7.3 Glaucoma Drugs: Market Forecast 2014-2024
7.4 Market Share of Leading Glaucoma Drugs to 2024
7.5 Glaucoma Drugs: Trends and Developments
7.5.1 Revenues Threatened by Patent Expiration
7.5.2 Preservative-Free Formulation Trends
7.5.3 Innovation in Treatments for Glaucoma
7.5.4 Simbrinza Launched as First Beta-Blocker-Free Combination
7.6 Lumigan and Ganfort (bimatoprost, Allergan)
7.6.1 Lumigan and Ganfort: Sales Forecast 2014-2024
7.7 Xalatan and Xalacom (latanoprost, Pfizer)
7.7.1 Xalatan/Xalacom: Sales Forecast 2014-2024
7.8 Travatan/Travatan Z and DuoTrav (travoprost, Novartis)
7.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024
7.9 Alphagan/Alphagan P and Combigan (brimonidine, Allergan)
7.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024
7.10 Trusopt and Cosopt/Cosopt PF (dorzolamide, Merck)
7.10.1 Trusopt: Sales Forecast 2014-2024
7.10.2 Cosopt and Cosopt PF: Sales Forecast 2014-2024
7.11 Azopt (brinzolamide, Novartis)
7.11.1 Azopt: Sales Forecast 2014-2024
7.12 Tapros (tafluprost, Santen)
7.12.1 Tapros/Taflotan: Sales Forecast 2014-2024
7.13 Zioptan (tafluprost, Akorn)
7.13.1 Zioptan: Sales Forecast 2014-2024
8. Dry Eye Drugs Market 2014-2024
8.1 Dry Eye: Introduction
8.2 Leading Dry Eye Drugs in 2013
8.3 Dry Eye Drugs: Market Forecast 2014-2024
8.4 Market Share of Leading Dry Eye Drugs to 2024
8.5 Dry Eye Drugs: Trends and Developments
8.5.1 Will Generic Restasis Launch in 2014?
8.5.2 Intensive Research Focus on Dry Eye
8.5.3 Improving Diagnostic Tools
8.6 Restasis (ciclosporin, Allergan)
8.6.1 Restasis: Sales Forecast 2014-2024
8.7 Refresh Brand Products (Allergan)
8.7.1 Refresh Brand Products: Sales Forecast 2014-2024
8.8 Hyalein (hyaluronic acid, Santen)
8.8.1 Hyalein: Sales Forecast 2014-2024
8.9 Diquas (diaquafosol, Santen)
8.9.1 Diquas: Sales Forecast 2014-2024
8.10 Other Ophthalmic Drugs
8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals)
8.10.2 Hetlioz: Sales Forecast 2014-2024
9. Leading Companies in the Ophthalmic Drugs Market
9.1 Novartis (Alcon)
9.1.1 Novartis: Ophthalmic Drugs Portfolio
9.1.2 Novartis: Sales Forecast 2014-2024
9.1.3 Novartis: Products in Development
9.1.4 Novartis: Recent Developments
9.1.4.1 Novartis Restructures Following Strategic Review
9.1.4.2 Novartis Licenses Ophthothech’s Fovista
9.2 Allergan
9.2.1 Allergan: Ophthalmic Drugs Portfolio
9.2.2 Allergan: Sales Forecast 2014-2024
9.2.3 Allergan: Products in Development
9.2.3.1 Novadur (Intravitreal Brimonidine Implant)
9.2.4 Allergan: Recent Developments
9.2.4.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.2.4.2 Prospects for Generic Restasis?
9.2.4.3 Allergan Rejects Valeant Bid
9.2.4.4 Allergan Considering Acquiring Shire?
9.3 Roche
9.3.1 Roche: Ophthalmic Drugs Portfolio
9.3.1.1 Lucentis: US Sales Forecast 2014-2024
9.3.2 Roche: Sales Forecast 2014-2024
9.3.3 Roche: Products in Development
9.4 Valeant
9.4.1 Valeant: Ophthalmic Drugs Portfolio
9.4.2 Valeant: Sales Forecast 2014-2024
9.4.3 Valeant: Products in Development
9.4.4 Valeant: Recent Developments
9.4.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
9.4.4.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals
9.5 Regeneron
9.5.1 Regeneron: Ophthalmic Drugs Portfolio
9.5.2 Regeneron: Sales Forecast 2014-2024
【レポート販売概要】
■ タイトル：世界の眼科医薬品市場予測：網膜疾患/アレルギー性炎症/緑内障/眼球乾燥症治療薬■ 英文：Ophthalmic Drugs Market Forecast 2014-2024
Prospects for Leading Companies
■ 発行日：2014年6月
■ 調査会社：visiongain
■ 商品コード：VISG409051
■ 調査対象地域：グローバル
- 世界のデータセンターラック市場動向（2012-2016）Introduction to the market Data center racks are equipment used to support servers, switches, routers, and other network-related devices. They enable efficient and easier management of data center networks. The racks are designed to hold multiple servers in a secure environment. Moreover, the racks come equipped with additional features that provide provisions for cooling, power distribution, conn …
- ラクトースフリー食品の世界市場Visiongain’s comprehensive new 154 page report reveals that the global lactose-free foods market will be worth $6.1bn in 2015. Mainly driven by an increasing demand for various types of lactose-free products, we forecast this market will grow with a mid-single digit CAGR during the next 10 years. Are you involved in the lactose-free foods market or intend to be? If so, then you must read this repo …
- Oil and Natural Gas Corporation Limited社の石油・ガス開発・生産動向及びコスト分析（2013年）Oil and Natural Gas Corporation Limited Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary Oil and Natural Gas Corporation Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. T …
- 下着の世界市場2015-2019About intimate apparel Intimate apparel is considered as the second skin of consumers, as it is the second layer of all other clothes. The success of the global intimate apparel market lies in understanding the right trend, deciding the appropriate time of launch, and selecting the right distribution store. Specialist lingerie retailers should keep in mind the price band and the average sales cycl …
- バイオフォトニック・医療機器用LEDのグローバル市場2014This report by ElectroniCast Consultants provides the research findings of our study of the worldwide consumption of packaged Light Emitting Diodes (LEDs), in Biophotonic and Medical Devices. This report provides global market data covering the years 2013-2020. The market data are segmented into the following geographic regions, plus a Global summary: - North, Central and South America (America) - …
- Tennessee Valley Authority：発電所及び企業SWTO分析2015Tennessee Valley Authority - Power Plants and SWOT Analysis, 2015 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - summari …
- Menveo (Meningococcal Vaccines)：市場予測と分析（～2022）Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Menveo (Meningococcal groups …
- Alexander Energy Ltd.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Alexander Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Alexander Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- アロマ成分の世界市場：合成成分、天然成分Aroma ingredient is a naturally or synthetically produced compound, which is added to food products or cosmetics to impart the desired fragrance. Natural aroma ingredients are extracted from natural sources such as flowers, fruits, wood, and spices, whereas synthetic aroma ingredients are produced from chemical compounds such as esters, aldehydes, alcohols, musk chemicals, and terpenes. Various me …
- アジアの電気生理処置機器市場見通し（～2021）Asia-Pacific Electrophysiology Procedures Outlook to 2021 Summary GlobalData’s new report, "Asia-Pacific Electrophysiology Procedures Outlook to 2021", provides key procedures data on the Asia-Pacific Electrophysiology Procedures. The report provides procedure volumes within market segment - Electrophysiology Ablation Procedures. The data in the report is derived from dynamic market forecast model …
- ゲーム機向けジェスチャ認識の世界市場About Gesture Recognition Gesture recognition is the ability of a device to identify and respond to different gestures, such as movement of hands, fingers, arms, head, or the entire body, of an individual. Gesture recognition technology can be 2D-based or 3D-based. It uses a camera-enabled device that beams an invisible infrared light onto the individual, which is reflected back to the camera and …
- 医薬品有効成分（原薬/API）の世界市場About Active Pharmaceutical Ingredients Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. They are used …
- イオン液体の世界市場の規模と予測：用途別（溶媒･触媒、抽出・分離、バイオ製油所、エネルギー貯蔵）、地域別（北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）、動向分析、2014-2025The global ionic liquid market is expected to reach USD 62.3 million by 2025, according to a new report by Grand View Research, Inc. The growing demand for the solvent & catalysis application which requires these liquids due to properties such as low vapor pressure and VOC content has boosted the growth of this industry. The extraction and separation application is mainly influenced by biodegradab …
- 緊急避妊ピルの世界市場2016-2020About Emergency Contraceptive (EC) Pills EC pills are short-term contraceptives used in the initial days after sexual intercourse to prevent pregnancy due to various uncertainties such as unprotected intercourse, coerced sex, forgotten pills, and condom breakage. These pills are only effective before the fertilization of the ovum by the sperm. As per WHO, levonorgestrel-based EC pills are ideal fo …
- グローバルにおける鎮痛剤注入ポンプ市場（2014-2018）About Analgesic Infusion Pumps Analgesic infusion pumps are devices used for pain management that deliver analgesic drugs into a patient’s body. Analgesic drug delivery provides relief from chronic disorders such as failed back syndrome, complex regional pain syndrome, pneumonia, tachycardia, hypertension, myocardial infarction, myocardial ischemia, and post-operative pain. Common medications used …
